N/A N=40 Is Non-Cardiac Chest Pain Caused by Sustained Longitudinal Smooth Muscle Contraction?
Chest Pain Atypical Syndrome
Primary: Mean Change in Esophageal Length With Acid — -0.40; -0.39 centimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 Chest Pain Perception and Capsaicin Sensitivity in Patients With Acute Cardiac Ischemia
Chest Pain
Primary: Capsaicin Sensitivity — 2.05 score on a scale
N/A N=28 Mindfulness-Based Stress Reduction for Adults With Low-Risk Chest Pain Associated With Anxiety
Chest Pain · Anxiety · Mindfulness
Primary: Mean Difference in Generalized Anxiety Disorder -7 (GAD-7) — 5.3; 3.2 score on a scale — p=0.82
N/A N=10,003 PROspective Multicenter Imaging Study for Evaluation of Chest Pain
Chest Pain
Primary: Time to Primary Endpoint — 1.0; 1.1; 1.2; 1.4 Percentage of participants with an event
N/A N=99 Chest Pain Perception and Capsaicin Sensitivity
Chest Pain
Primary: Capsaicin Sensitivity — 2.47 score on a scale
Phase 4 N=51 EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia
Ischemic Heart Disease
Primary: Epicardial Coronary Artery Endothelial Function (Adjusted) at Week 16 Comparing the Eplerenone Group to the Placebo Group — -1.2; -10.7 % change wk16-%change wk0…
N/A N=251 PCP Use of a Gene Expression Test (Corus CAD or ASGES) in Coronary Artery Disease Diagnosis
Chest Pain · Cardiovascular Diseases · Angina Pectoris
Primary: Change in Clinicians' Treatment Decision After Age/Sex/Gene Expression Score — 38; 1; 1; 0 number of subjects — p=<0.001
Phase 4 N=13 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain
Chest Pain
Primary: Frequency of Chest Pain Episodes — 1; 3 participants
N/A N=34 Comparative Effectiveness of Decision Aids for Stable Chest Discomfort
Coronary Artery Disease · Stable Angina
Primary: Total Knowledge Score — 2.83; 4.0 knowledge score
N/A N=602 Early Risk Stratification in ED Chest Pain Patients
Acute Coronary Syndrome
Primary: Number of Patients With Major Adverse Cardiac Event — 42; 0; 437; 123 Participants
Phase 4 N=59 Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Acute Chest Pain
Chest Pain Syndrome
Primary: Length of Hospital Stay — 7.63; 8.20 Hours — p=0.79
Phase 4 N=31 Ranolazine and Microvascular Angina by PET in the Emergency Department
Microvascular Angina
Primary: Coronary Flow Reserve — 1.6; 1.6; 1.9; 1.6 ratio
N/A N=1,392 Computed Tomography Coronary Angiogram (CTCA) Versus Traditional Care in Emergency Department Assessment of Potential Acute Coronary Syndromes (ACS)
Chest Pain · Acute Coronary Syndrome · Acute Myocardial Infarction
Primary: Rates of Major Cardiac Events (AMI or Cardiac Death) Within 30 Days — 0; 0; 0; 10 Participants
N/A N=105 Randomized Investigation of Chest Pain Diagnostic Strategies
Acute Coronary Syndrome · Chest Pain
Primary: The Composite of Revascularization, Re-hospitalization, and Recurrent Cardiac Testing Through 90 Days. — 7; 20 participants
Phase 4 N=171 An Open-label, Multi-center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-release Tablets (CVT 3041)
Chronic Angina
Primary: Evaluate the Validity of the WISQ in Women With Chronic Angina Based on Changes in Patient-reported Angina Frequency and Nitroglycerin (NTG) Consumption Before and…
N/A N=541 Assessment of Acute Disease to Reduce Imaging Costs
Acute Coronary Syndrome · Pulmonary Embolism
Primary: Efficiency--Mean Cost of Care — 3933; 2761 US Dollars
Phase 4 N=14 Ranolazine for the Treatment of Chest Pain in HCM Patients
Hypertrophic Cardiomyopathy
Primary: QT Interval — 462.8 msec
N/A N=169 Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes
Chronic Obstructive Pulmonary Disease · Acute Coronary Syndromes
Primary: COPD Diagnosis — 39 participants
N/A N=80 Lidocaine 5% Patch (Lidoderm) for the Prevention of Acute and Chest Pain Following Robotic Valve Surgery
Perioperative Chest Pain
Primary: Pain Disability Index Score (PDI) at Six Months Following Surgical Procedure — 26; 30; 12; 13 units on a scale — p=0.28
N/A N=150 Stress CT Perfusion in Patients With Chest Pain
Coronary Artery Disease
Primary: Number of Participants With Detected Stress-induced Perfusion Abnormalities by 3D Analysis of MDCT Images — 56 Participants
Phase 4 N=28 Ranolazine in Ischemic Cardiomyopathy
Cardiomyopathy · Chest Pain · Dyspnea
Primary: Anginal Frequency — 86.67; 74.44 units on a scale — p=0.058
Phase 4 N=33 Impact of Ranolazine in Blood Markers in Women With Angina and Metabolic Syndrome
Stable Angina · Metabolic Syndrome
Primary: Impact of Ranolazine on Hemoglobin A1C — -5; 2.6 percent change
N/A N=871 Risk Markers in the Acute Coronary Syndromes
Chest Pain · Coronary Artery Disease · Unstable Angina Pectoris
Primary: Total Mortality. — 138 Participants.
N/A N=374 The Primary Symptoms of GERD(Gastroesophageal Reflux Disease) in Chinese Outpatients in Gastroenterology Department
Gastroesophageal Reflux
Primary: The Primary Symptom of GERD in Chinese Outpatients in Gastroenterology Department — 19; 30; 42; 23 Participants
N/A N=203 Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?
Coronary Artery Disease
Primary: Estimation of Number of Cases Where FFR Data Results in a Change in the Management Strategy (Number of Vessel Requiring Treatment and/or PCI vs Medical vs CABG) — 147…
Phase 4 N=12 Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease
Microvascular Angina
Primary: Seattle Angina Questionnaire Score — 83.3; 29.2; 74.1; 67.6 units on a scale
Phase 4 N=70 Aspirin Dose and Atherosclerosis in Patients With Metabolic Syndrome
Cardiovascular Diseases · Metabolic Syndrome X · Atherosclerosis
Primary: Change in Nitric Oxide Formation From Baseline to 3 Months — 27.6; 27.0; 31.4; 25.7 ng/mL
N/A N=1,748 Rapid Assessment of Potential Ischaemic Heart Disease With CTCA
Acute Coronary Syndrome
Primary: All-cause Death or Subsequent Non-fatal Type 1 or Type 4b MI at One Year Measured as Time to First Such Event. — 51; 53 Participants
Phase 2 N=14 Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)
Sensitivity in Esophagus
Primary: Time to Visual Analogue Scale 7 (VAS7) During Thermal Stimulation at 1.5 Hours Post-Dose. — 84.0; 86.9 seconds
Phase 3 N=292 Functional Dyspepsia Treatment Trial
Dyspepsia and Other Specified Disorders of Function of Stomach
Primary: Self-Report of Adequate Relief of Dyspepsia (Yes/No) For at Least 50% of Weeks 3 -12 of Treatment — 53; 38; 40 percentage of participants — p=0.05